Read on Twitter
0/6
Background: Liquid biopsies have the potential to become an invaluable tool in the management of #cancer.
That’s why, it is important to generate solid evidence to define areas in which they can guide treatment decisions.
@OncoAlert
#LiquidBiopsies #PrecisionMedicine
Background: Liquid biopsies have the potential to become an invaluable tool in the management of #cancer.
That’s why, it is important to generate solid evidence to define areas in which they can guide treatment decisions.
@OncoAlert
#LiquidBiopsies #PrecisionMedicine
1/6
Accordingly, this paper by @LizzySmyth1 & team in @myESMO @Annals_Oncology on the prognostic value of longitudinal ctDNA
assessment in #EsophagealCancer #esocsm addresses a very relevant question.
@OncoAlert #PrecisionMedicine #LiquidBiopsies https://www.annalsofoncology.org/article/S0923-7534(20)43216-8/fulltext
Accordingly, this paper by @LizzySmyth1 & team in @myESMO @Annals_Oncology on the prognostic value of longitudinal ctDNA
assessment in #EsophagealCancer #esocsm addresses a very relevant question. @OncoAlert
#PrecisionMedicine #LiquidBiopsies https://www.annalsofoncology.org/article/S0923-7534(20)43216-8/fulltext
2/6
97 patients that underwent neo-adjuvant chemotherapy & resection with a total of 245 available samples were identified in 
OCCAMS consortium dataset.
Samples were analysed w a pan #cancer ctDNA panel
@OncoAlert
97 patients that underwent neo-adjuvant chemotherapy & resection with a total of 245 available samples were identified in OCCAMS consortium dataset. Samples were analysed w a pan #cancer ctDNA panel@OncoAlert
3/6
Importantly (!), in contrast to other papers, the team decided to assess clonal hematopoiesis w indeterminate potential (CHIP) to tease out #cancer specific ctDNA. This is important, as this step is not necessarily standard (but should be).
@KlausMetzelerMD @OncoAlert
Importantly (!), in contrast to other papers, the team decided to assess clonal hematopoiesis w indeterminate potential (CHIP) to tease out #cancer specific ctDNA. This is important, as this step is not necessarily standard (but should be).
@KlausMetzelerMD @OncoAlert
4/6
Before filtering CHIP
16/79 (20%) pts has ctDNA post surgery
12/16 (75%) relapsed
After filtering CHIP
10/63 (17%) pts had ctDNA post surgery
9/10 (90%) relapsed
This underscores the importance of taking CHIP into account
@KlausMetzelerMD @OncoAlert
Before filtering CHIP
16/79 (20%) pts has ctDNA post surgery 12/16 (75%) relapsed After filtering CHIP
10/63 (17%) pts had ctDNA post surgery 9/10 (90%) relapsed This underscores the importance of taking CHIP into account
@KlausMetzelerMD @OncoAlert
5/6
Importantly, these findings had prognostic implications:
Median #Cancer specific survival
w/o CHIP
ctDNA pos pats 14.9 months
ctDNA neg pats 29.5 months
HR 2.32
w CHIP
ctDNA pos pats 10 months
ctDNA neg pats 29.9 months
HR: 5.55
@Annals_Oncology @OncoAlert
Importantly, these findings had prognostic implications:
Median #Cancer specific survival
w/o CHIP
ctDNA pos pats 14.9 monthsctDNA neg pats 29.5 monthsHR 2.32
w CHIP
ctDNA pos pats 10 monthsctDNA neg pats 29.9 monthsHR: 5.55
@Annals_Oncology @OncoAlert
6/6
While the numbers are small, this paper shows that assessment of ctDNA holds great potential in various settings such as
risk stratification
disease monitoring
allocation to clinical trials
& many many more…
Thanks to @LizzySmyth1 & team for their efforts!
While the numbers are small, this paper shows that assessment of ctDNA holds great potential in various settings such as
risk stratification disease monitoring allocation to clinical trials& many many more…
Thanks to @LizzySmyth1 & team for their efforts!
